The use of cell-mediated immunity for the evaluation of influenza vaccines: an upcoming necessity
Influenza vaccines are a fundamental tool for preventing the disease and reducing its consequences, particularly in specific high-risk groups. In order to be licensed, influenza vaccines have to meet strict criteria established by European Medicines Agency. Although the licensure of influenza vaccin...
Main Authors: | E Gianchecchi, A Torelli, E Montomoli |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2019-05-01
|
Series: | Human Vaccines & Immunotherapeutics |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/21645515.2019.1565269 |
Similar Items
-
Immunogenicity and Safety of the New Inactivated Quadrivalent Influenza Vaccine Vaxigrip Tetra: Preliminary Results in Children ≥6 Months and Older Adults
by: Emanuele Montomoli, et al.
Published: (2018-03-01) -
Immunogenicity Measures of Influenza Vaccines: A Study of 1164 Registered Clinical Trials
by: Alexander Domnich, et al.
Published: (2020-06-01) -
Antibody and Cell-Mediated Immune Responses Are Correlates of Protection against Influenza Infection in Vaccinated Older Adults
by: Chris P. Verschoor, et al.
Published: (2021-01-01) -
Heterosybtypic T-cell immunity to influenza in humans: challenges for universal T-cell influenza vaccines
by: Saranya eSridhar
Published: (2016-05-01) -
The role of cell-mediated immunity against influenza and its implications for vaccine evaluation
by: Yorick Janssens, et al.
Published: (2022-08-01)